about
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroOlomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors.In vitro transfection mediated by dendrigraft poly(L-lysines): the effect of structure and molecule size.Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat.Nitric oxide is involved in light-specific responses of tomato during germination under normal and osmotic stress conditions.Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility.Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer TreatmentAldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profileRoscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatmentBrivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation EnzymesBuparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug ResistanceCyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters
P50
Q28534229-8FAB2FDA-6893-4417-A846-16289D793B74Q28537944-376436DC-8882-4147-B41E-96FB026AFD0AQ34102279-7951D44B-E160-4E28-AF77-7E0E4A6A5621Q38803043-C9A9C290-1CAC-4FC4-BD0D-185965BB1B11Q38873439-5C080ADF-5CDA-4DD1-A94E-3DC5C9984631Q38994604-902C6BBC-647D-4EEA-AE81-EEA20D58954CQ39203004-E6ECE58F-3833-4258-858F-EDF972BBFE5AQ39227454-8F6967EE-FA4A-4757-88B5-A90E932378ABQ39356896-F9F9B846-B251-4D6C-9792-E97F95940305Q42083584-8168D5C1-2F69-4E50-A92B-B1268F1AD7E6Q43271761-99D2E731-3A6B-4A2B-A2B1-EB46A527464AQ52576947-C760E8C0-6BE1-4FA1-8570-7C8CEBAB676BQ53818047-A5F96551-CE0C-4015-977B-F7ECE4682C3EQ58929969-A0FCD66B-92B9-4573-9A3D-DE99CAA784DAQ89543485-A5BDAA85-A6E9-472C-8C10-029D2247825DQ90754922-06575595-B414-4415-80A5-0F13F2A5BE24Q90843029-0F1C7A01-9DEF-4CCF-8519-E7A501763492Q91291307-F2EED426-48D7-4625-BDAC-2AF9E79DD361Q91862407-57360E63-AB5D-4F98-AC3A-7D6BFA60C428Q92073954-D9E56458-3FA4-4222-B429-9117AEE556CD
P50
description
researcher
@en
հետազոտող
@hy
name
Jakub Hofman
@ast
Jakub Hofman
@en
Jakub Hofman
@es
Jakub Hofman
@nl
Jakub Hofman
@sl
type
label
Jakub Hofman
@ast
Jakub Hofman
@en
Jakub Hofman
@es
Jakub Hofman
@nl
Jakub Hofman
@sl
altLabel
Hofman J
@en
Hofman J.
@en
Hofman Jakub
@en
J Hofman
@en
Jakub Hofman
@en
prefLabel
Jakub Hofman
@ast
Jakub Hofman
@en
Jakub Hofman
@es
Jakub Hofman
@nl
Jakub Hofman
@sl
P1053
T-6461-2017
P106
P108
P1153
35269232100
P31
P3829
P496
0000-0002-4285-7681